The case for & against
Bull & Bear analysis
Bullish
Collegium Pharmaceutical (NASDAQ: COLL) is an emerging biopharmaceutical company focused on developing and commercializing innovative products for the treatment of pain and attention-deficit/hyperactivity disorder (ADHD). The company has established a strong market position with its ADHD franchise, particularly with products like JORNAY PM® and AZSTARYS®. Furthermore, it is navigating changes in the opioid pain management landscape, making it part of the ongoing evolution in pain management therapies.
Bull says
- ↑Q2 product revenues $199.9M (+6% YoY); JORNAY PM +41% YoY; AZSTARYS $12.9M
- ↑$50M accelerated share repurchase underscores management confidence
- ↑Shares at $25.68 vs $46.67 intrinsic value (~45% undervalued)
- ↑Non-GAAP net income $75.4M; adjusted EBITDA $113.8M (+8% YoY) shows strong margins
- ↑High earnings yield and growth factor support future earnings expansion
- ↑Robust ADHD franchise provides runway for continued market share gains
Bear says
- ↓Full-year 2026 revenue guidance cut amid 9% pain portfolio decline
- ↓GAAP net loss of $15.1M contrasts with positive adjusted metrics
- ↓High short interest and negative momentum indicate bearish sentiment
- ↓No dividends or cash returns may deter income-focused investors
- ↓Intensifying competition in ADHD and pain markets could pressure margins
- ↓Weak revision and size factors suggest limited analyst optimism
Investment themes with COLL
Pharmaceuticals↓ -0.48%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-09-2025bullish
Transcript signals
Bull points
- At Collegium, we're proud to be the leader in responsible pain management and to offer a differentiated portfolio of products for the treatment of pain.
- Belbuca, Xtampza ER and Nucynta ER have a combined 50% share of the branded ER market, demonstrating the ongoing strength and reach of our portfolio.
- Belbuca and Xtampza ER are well positioned for growth this year and the Nucynta Franchise continues to be a key contributor.
Read full transcript analysis ›